first
synthet
compound
shown
inhibit
influenzaviru
replic
amantadin
indic
fig
amantadin
block
migrat
h
ion
interior
viru
particl
virion
within
endosom
process
need
uncoat
occur
h
ion
import
matrix
channel
transmembran
domain
protein
aminoacid
residu
face
ionconduct
pore
shown
fig
ref
amantadin
postul
block
interior
channel
within
tetramer
helix
bundl
adamantan
amin
e
deriv
amantadin
rimantadin
fig
long
avail
prophylaxi
therapi
influenza
viru
infect
use
limit
rapid
emerg
drug
resist
readi
transmiss
drugresist
virus
particularli
amantadin
occurr
central
nervou
system
cn
side
effectsthes
drawback
compromis
potenti
use
amantadin
rimantadin
use
singl
agent
treatment
avian
human
influenza
viru
infect
particular
incid
adamantan
resist
among
influenza
virus
isol
unit
state
worldwid
caus
concern
adamantaneresist
isol
identifi
worldwid
contain
substitut
global
circul
adamantaneresist
virus
unpreced
seem
mediat
continu
select
drug
pressur
could
argu
resist
exist
rel
homogen
strain
antivir
use
would
curtail
suscept
strain
might
emerg
adamantan
might
regain
util
epidem
pandem
influenza
structur
mimic
intermediari
state
reactant
product
given
reaction
addit
amantadin
rimantadin
variou
new
adamantan
amin
e
deriv
shown
mark
activ
influenza
andor
fig
whether
new
deriv
might
offer
advantag
term
potenc
select
safeti
resist
profil
parent
compound
amantadin
rimantadin
need
explor
also
investig
antivir
potenti
cagelik
compound
structur
relat
adamantyl
entiti
bananin
might
worthwhil
present
specul
whether
new
adamantan
amin
e
deriv
might
activ
amantadineresist
variant
efficaci
vivo
human
relev
anim
model
viral
haemagglutinin
h
need
viru
interact
receptor
bear
nacetylneuramin
acid
nana
sialic
acid
viral
neuraminidas
n
cleav
nana
cellsurfac
glycoprotein
specif
bond
sialic
acid
link
galactos
linkag
sialic
acid
link
galactos
linkag
fig
enabl
progeni
virion
leav
infect
cell
spread
host
cell
block
releas
newli
form
viru
particl
neuraminidas
inhibitor
prevent
spread
viru
fig
neuraminidas
might
also
role
earli
influenza
infect
human
airway
epithelium
avian
influenza
virus
human
influenza
virus
seem
target
differ
receptor
human
respiratori
tract
wherea
humanderiv
virus
preferenti
recogn
locat
epitheli
cell
nasal
mucosa
paranas
sinus
pharynx
trachea
bronchi
avian
virus
seem
preferenti
recogn
locat
deepli
respiratori
tract
alveolar
cell
wall
junction
respiratori
bronchiol
alveolu
avian
influenza
viru
might
caus
sever
lower
respiratori
tract
lrt
diseas
human
attach
predominantli
type
ii
pneumocyt
alveolar
macrophag
noncili
bronchiolar
cell
human
lrt
term
effect
neuraminidas
inhibitor
would
theori
matter
whether
nana
bound
linkag
neuraminidas
inhibitor
act
transit
state
analogu
nana
irrespect
bound
penultim
galactos
unit
oseltamivir
zanamivir
first
neuraminidas
inhibitor
design
accord
transit
state
analogu
principl
dana
acid
fana
acid
spanish
influenza
viru
close
relat
avian
viru
adapt
replic
effici
human
reassort
event
led
respect
asian
influenza
viru
hong
kong
influenza
viru
asian
influenza
viru
acquir
three
genet
segment
avian
speci
haemagglutinin
h
neuraminidas
n
polymeras
gene
hong
kong
influenza
viru
acquir
two
genet
segment
avian
speci
h
futur
pandem
strain
could
aris
either
mechan
receptor
contain
sialic
acid
serv
lead
compound
develop
neuraminidas
inhibitor
market
present
treatment
prophylaxi
influenza
b
viru
infect
zanamivir
relenza
oseltamivir
tamiflu
ethyl
ester
fig
compound
found
highli
potent
inhibitor
ic
ng
ml
influenza
neuraminidas
inhibit
influenza
b
viru
replic
vitro
vivo
mice
ferret
well
toler
prophylact
signific
reduct
number
ill
subject
therapeut
signific
reduct
durat
ill
effect
influenza
b
viru
infect
human
crucial
differ
zanamivir
oseltamivir
howev
zanamivir
administ
inhal
mg
twice
daili
wherea
oseltamivir
administ
oral
mg
twice
daili
neuraminidas
inhibitor
anticip
reduc
ill
durat
day
reduc
risk
viru
transmiss
household
healthcar
contact
reduc
number
sever
complic
sinus
bronchiti
reduc
use
antibiot
prevent
season
influenzaviru
infect
shown
particular
oseltamivir
earlier
administr
shorter
durat
fever
greater
allevi
symptom
faster
return
baselin
activ
health
score
oseltamivir
treatment
influenza
ill
reduc
lower
respiratori
tract
complic
particularli
bronchiti
pneumonia
concomitantli
reduct
antibiot
use
need
hospit
also
postexposur
prophylaxi
oseltamivir
mg
daili
seven
day
found
protect
close
contact
influenzainfect
person
influenza
ill
prevent
spread
within
household
postexposur
prophylaxi
oseltamivir
consid
effect
option
prevent
transmiss
influenza
within
household
recogn
howev
oseltamivir
less
effect
influenza
b
influenza
regard
durat
fever
viru
persist
neuraminidas
inhibitor
found
posit
activ
centr
neuraminidas
fig
two
structur
influenza
viru
neuraminidas
solv
first
contain
neuraminidas
second
contain
neuraminidas
fig
neuraminidas
inhibitor
make
contact
arginin
posit
carboxyl
acid
group
glutam
acid
posit
basic
amin
case
oseltamivir
guanidinium
case
zanamivir
group
surpris
posit
mutat
aris
engend
resist
zanamivir
oseltamivir
mutat
caus
highlevel
resist
oseltamivir
lowlevel
resist
zanamivir
comprehens
studi
clinic
influenza
isol
recov
evid
natur
occur
resist
either
oseltamivir
zanamivir
isol
howev
children
treat
influenza
oseltamivir
kiso
et
al
found
neuraminidas
mutat
virus
nine
patient
six
mutat
posit
two
posit
zanamivirresist
influenza
virus
might
readili
aris
vivo
owe
poor
viabil
reduc
fit
recombin
virus
contain
either
wildtyp
neuraminidas
singl
aminoacid
chang
residu
gener
influenza
viru
revers
genet
mutant
show
decreas
sensit
oseltamivir
viru
show
crossresist
zanamivir
mutat
associ
compromis
viral
growth
transmiss
accord
earlier
studi
wherea
growth
transmiss
viru
compar
wildtyp
viru
note
influenza
viru
carri
mutat
neuraminidas
gene
transmit
ferret
condit
wildtyp
viru
readili
transmit
howev
mutant
virus
influenza
engend
resist
oseltamivir
found
readili
transmiss
ferret
although
mutant
requir
higher
dose
infect
transmit
slowli
wild
type
bind
sialicacid
receptor
influenza
virion
intern
receptormedi
endocytosi
low
ph
endosom
trigger
fusion
viral
endosom
membran
influx
h
ion
channel
releas
viral
rna
gene
cytoplasm
adamantan
amin
e
deriv
block
uncoat
step
rna
replic
transcript
occur
nucleu
process
block
inhibitor
inosin
imp
dehydrogenas
cellular
enzym
viral
rna
polymeras
stabil
viral
mrna
translat
viral
protein
might
prevent
small
interf
rna
sirna
packag
bud
virion
occur
cytoplasm
membran
neuraminidas
n
inhibitor
block
releas
newli
form
virion
infect
cell
figur
use
neuraminidas
inhibitor
therapi
prophylaxi
influenza
b
viru
infect
consid
new
millennium
conundrum
stockpil
zanamivir
andor
oseltamivir
propos
prepar
influenza
pandem
also
hypothes
compound
could
theori
also
inhibit
viru
caus
pandem
fact
recombin
virus
possess
neuraminidas
neuraminidas
haemagglutinin
shown
effect
inhibit
vitro
vivo
mice
zanamivir
oseltamivir
recombin
viru
possess
ion
channel
could
effect
inhibit
amantadin
rimantadin
indic
current
antivir
strategi
could
effect
curb
reemerg
influenza
viru
recent
resist
influenza
viru
oseltamivir
owe
mutat
neuraminidas
gene
describ
patient
oseltamivirresist
strain
isol
recov
diseas
viru
found
less
pathogen
ferret
parent
strain
show
crossresist
zanamivir
although
mutat
influenza
neuraminidas
previous
report
occurr
influenza
infect
rais
concern
associ
death
two
eight
influenza
infect
patient
howev
whether
causal
relationship
emerg
mutat
lethal
outcom
establish
efficaci
oseltamivir
treatment
infect
human
could
anecdot
use
unequivoc
shown
howev
note
oseltamivir
shown
protect
ferret
lethal
influenza
infect
treatment
oseltamivir
mg
kg
per
day
day
twice
daili
oral
result
complet
inhibit
viru
replic
lung
small
intestin
day
postinfect
consequ
prevent
mortal
similarli
oseltamivir
proven
efficaci
treatment
mice
infect
highli
pathogen
influenza
strain
although
prolong
higherdos
oseltamivir
regimen
requir
achiev
benefici
antivir
effect
fig
addit
acid
deriv
describ
influenzaneuraminidas
inhibitor
albeit
reduc
inhibitori
potenc
compar
correspond
pyrrolidin
analogu
peramivir
retain
activ
variou
zanamivirand
oseltamivirresist
influenza
b
virus
specif
new
oseltamivirresist
influenza
b
variant
carri
substitut
viral
neuraminidas
found
retain
suscept
peramivir
addit
neuraminidas
mutant
show
lower
suscept
oseltamivir
lower
suscept
zanamivir
wildtyp
viru
retain
full
suscept
ref
taken
togeth
studi
perform
influenza
viru
mutant
indic
neuraminidas
inhibitor
might
select
mutat
sever
posit
partial
overlap
partial
engend
crossresist
vivo
peramivir
found
strongli
suppress
influenza
infect
mice
follow
singl
intramuscular
inject
mg
kg
ascrib
tight
bind
peramivir
neuraminidas
similarli
singl
intramuscularintraven
inject
peramivir
one
hour
viru
exposur
offer
protect
influenza
mice
given
oral
human
howev
peramivir
offer
robust
protect
human
influenza
infect
attribut
low
oral
bioavail
peramivir
studi
parenter
formul
peramivir
therefor
warrant
start
zanamivir
ether
deriv
bicycl
ether
deriv
synthes
show
improv
influenza
viru
plaquereduct
activ
vitro
improv
oral
efficaci
vivo
mice
respect
compar
parent
compound
zanamivir
dimer
deriv
zanamivir
link
group
atom
length
found
potent
inhibitor
influenzaviru
replic
vitro
vivo
zanamivir
compound
show
longlast
antivir
activ
owe
extrem
long
persist
time
lung
allow
onceweekli
dose
regimen
rais
prospect
new
type
antiinfluenza
drug
could
administ
singl
dose
treatment
influenza
week
prevent
infect
ribavirin
long
recogn
broadspectrum
antivir
agent
particularli
distinct
activ
orthomyxovirus
influenza
paramyxovirus
measl
respiratori
syncyti
viru
rsv
rsv
infect
rna
viru
infect
aerosol
ribavirin
formal
approv
oral
ribavirin
also
use
combin
parenter
pegyl
treatment
chronic
hepat
c
viru
hcv
infect
intraven
form
ribavirin
regist
treatment
haemorrhag
fever
renal
addit
poli
ethylen
glycol
peg
group
protein
increas
resist
proteolyt
degrad
improv
water
solubl
reduc
antigen
pharmacolog
inact
compound
convert
activ
form
drug
endogen
enzym
metabol
gener
design
overcom
problem
associ
stabil
toxic
lack
specif
limit
oral
bioavail
sirna
small
nucleotid
rna
construct
interfer
rna
translat
antisens
oligonucleotid
phosphat
group
replac
thiophosph
group
syndrom
hfr
addit
ribavirin
viramidin
consid
amidin
prodrug
ribavirin
fig
accredit
mark
potenti
antiinfluenza
drug
ribavirin
notabl
gener
drug
resist
resist
influenzaviru
replic
ribavirin
best
knowledg
report
far
obvious
lack
drugresist
due
fact
ribavirin
main
target
antivir
action
cellular
enzym
inosin
imp
dehydrogenas
respons
convers
imp
xanthosin
key
enzym
involv
biosynthesi
gtp
viral
rna
synthesi
fig
ribavirin
activ
human
avian
influenza
virus
within
effect
concentr
ec
rang
three
rout
oral
aerosol
intraven
ribavirin
could
administ
treatment
influenza
intraven
rout
prefer
therapi
acut
influenzaviru
infect
oral
ribavirin
offer
expect
clinic
virolog
efficaci
earlier
studi
influenza
ribavirin
aerosol
use
success
base
reduct
viru
shed
clinic
symptom
treatment
influenzaviru
infect
colleg
student
intraven
ribavirin
produc
mean
plasma
concentr
associ
symptomat
improv
elimin
influenza
viru
nasopharyng
swab
tracheal
aspir
intraven
ribavirin
investig
success
treatment
lassa
fever
hfr
studi
show
signific
benefit
ribavirin
term
surviv
reduct
diseas
sever
dose
regimen
intraven
ribavirin
consist
load
dose
gram
ribavirin
follow
gram
everi
hour
day
follow
day
administ
mainten
dose
gram
everi
hour
gener
concentr
need
achiev
suppress
human
avian
influenzaviru
replic
doselimit
toxic
would
haemolyt
anaemia
revers
cessat
therapi
recent
recombin
fusion
protein
compos
sialidas
neuraminidas
catalyt
domain
deriv
actinomyc
viscosu
fuse
cellsurfaceanchor
sequenc
report
novel
broadspectrum
inhibitor
influenzaviru
infect
sialidas
fusion
protein
appli
topic
inhal
remov
influenzaviru
receptor
sialic
acid
airway
epithelium
sialidas
fusion
construct
fludas
shown
effect
cleav
sialicacid
receptor
use
human
avian
influenza
virus
show
potent
antivir
cellprotect
efficaci
panel
laboratori
strain
clinic
isol
influenza
influenza
b
virusrepl
inhibit
ec
valu
rang
nm
signific
vivo
efficaci
sialidas
fusion
construct
note
prophylact
therapeut
approach
sialicacid
receptor
could
also
target
sialicacid
polyacrylamid
conjug
also
term
sialylglycopolym
sialylglycopolym
inhibit
influenzaviru
attach
cell
vivo
administ
aerosol
form
within
hour
infect
found
complet
prevent
mortal
mice
infect
mouseadapt
influenza
strain
sialylglycopolym
target
receptor
determin
recogn
human
influenza
b
virus
would
make
potenti
valuabl
protect
newli
emerg
human
influenza
viru
strain
sirna
phosphorothio
oligonucleotid
small
interf
rna
sirna
specif
conserv
region
influenzaviru
gene
found
reduc
viru
product
lung
infect
mice
sirna
given
intraven
complex
polyc
carrier
either
initi
viru
infect
deliveri
sirna
specif
highli
conserv
region
nucleoprotein
acid
polymeras
significantli
reduc
lung
viru
titr
mice
infect
influenza
viru
protect
anim
lethal
challeng
protect
specif
mediat
antivir
interferon
respons
influenzaspecif
sirna
treatment
broadli
effect
protect
anim
lethal
challeng
highli
pathogen
avian
influenza
virus
subtyp
could
predict
specif
sirna
would
effect
influenza
equal
effect
result
obtain
specif
sirna
sar
sever
acut
respiratori
syndrom
coronaviru
compar
situat
phosphorothio
oligonucleotid
pson
rep
pson
offer
potenti
administ
aerosol
prophylaxi
therapi
influenza
infect
similarli
antisens
phosphorodiamid
morpholino
oligom
arppmo
could
pursu
potenti
treatment
influenza
viru
infect
influenzaviru
rna
polymeras
consist
complex
three
virusencod
polypeptid
pa
addit
rna
replic
activ
also
contain
endonucleas
activ
ensur
cap
snatch
initi
transcript
subsequ
translat
process
polymerasecomplex
gene
contribut
high
virul
human
influenzaviru
isol
ref
observ
highlight
import
novel
antivir
target
polymeras
develop
therapi
prophylaxi
human
avian
influenzaviru
infect
compound
report
oper
either
rna
replicas
rna
polymeras
endonucleas
level
like
inhibitor
found
inhibit
revers
transcriptas
rnadepend
dna
polymeras
hiv
rna
replicas
rnadepend
rna
polymeras
hcv
influenza
rnareplicas
inhibitor
divid
two
class
fig
substitut
pyrazin
potent
antiinfluenzaviru
activ
vitro
vivo
accord
compar
studi
would
even
potent
oseltamivir
increas
multipl
infect
vitro
use
higher
viruschalleng
dose
vivo
postul
convert
intracellularli
ribonucleotid
rmp
phosphoribosyl
transferas
phosphoryl
fig
rtp
would
inhibit
influenzaviru
rna
polymeras
gtpcompetit
manner
unlik
ribavirin
rmp
significantli
inhibit
imp
dehydrogenas
indic
owe
antiinfluenza
viru
activ
mainli
exclus
inhibit
influenzaviru
rna
polymeras
addit
rna
polymeras
cap
snatch
cap
scaveng
endonucleas
activ
associ
complex
could
attract
target
influenzaviru
inhibitor
inhibit
acid
deriv
nhydroxam
acidnhydroxyimid
deriv
likewis
flutimid
fig
identifi
extract
fungal
speci
delitschia
confertaspora
shown
specif
inhibit
capdepend
endonucleas
activ
associ
influenza
viral
rna
polymeras
inhibit
replic
influenza
b
viru
cell
cultur
viral
rna
polymeras
endonucleas
explor
target
develop
antiinfluenza
agent
recent
new
class
potent
influenzaviru
inhibitor
ec
viru
replic
report
repres
thiadiazolo
pyrimidin
pyrimidinyl
acylthiourea
fig
although
mechan
action
class
highli
potent
select
inhibitor
influenza
viru
remain
establish
repres
highli
interest
lead
worth
pursu
seri
novel
bisheterocycl
tandem
deriv
consist
methyloxazol
thiazol
might
also
serv
lead
optim
although
lead
compound
show
modest
activ
influenza
viru
interferon
origin
discov
almost
year
ago
influenza
viru
induc
fact
baron
isaac
allud
absenc
interferon
lung
fatal
case
influenza
earlier
studi
interferon
instil
intranas
rout
offer
signific
protect
prophylaxi
influenzaaviru
infect
sinc
pegyl
inject
parenter
combin
oral
ribavirin
becom
standard
therapi
chronic
hcv
infect
extens
experi
combin
accumul
could
readili
implement
prophylaxi
therapi
human
well
avian
influenzaviru
infect
human
prophylaxi
therapi
influenzaviru
infect
durat
treatment
would
much
shorter
treatment
hepat
c
would
obvious
affect
conveni
costbenefit
side
effect
inher
link
use
interferon
ribavirin
addit
interferon
interferon
induc
poli
c
discov
year
ago
might
also
role
control
influenzaviru
infect
prophylaxi
use
liposomeencapsul
doublestrand
rna
poli
c
provid
complet
longlast
protect
influenza
infect
furthermor
combin
intranas
vaccin
poli
c
confer
complet
protect
influenzaviru
infect
might
mediat
upregul
express
tolllik
receptor
well
h
h
cytokin
unclear
whether
use
exogen
interferon
induct
endogen
interferon
poli
poli
c
doublestrand
rna
might
help
prophylaxi
therapi
avian
human
influenzaviru
infect
view
renaiss
interferon
treatment
hcv
infect
potenti
interferon
influenza
might
well
deserv
revisit
signaltransduct
inhibitor
target
either
erbb
tyrosin
kinas
abl
kinas
famili
figur
imp
dehydrogenas
inhibit
viramidin
act
prodrug
precursor
ribavirin
convert
intracellularli
deriv
ribavirinmp
latter
inhibit
inosin
imp
dehydrogenas
crucial
enzym
biosynthesi
rna
includ
viral
rna
imp
dehydrogenas
respons
convers
imp
xanthosin
xmp
turn
convert
gmp
guanosin
gdp
guanosin
gtp
guanosin
latter
serv
substrat
togeth
atp
utp
ctp
synthesi
rna
imatimib
recent
shown
suppress
vitro
replic
vivo
dissemin
poxvirus
likewis
signal
cascad
could
consid
attract
opportun
futur
strategi
block
influenzaviru
product
export
influenzaviru
ribonucleoprotein
rnp
nucleu
depend
cellular
rafmekerk
kinas
mapk
signal
cascad
activ
erk
signal
specif
trigger
accumul
influenzaaviru
haemagglutinin
cell
membran
erk
activ
could
therefor
consid
potenti
target
intervent
influenzaviru
propag
recent
site
protein
influenza
viru
propos
potenti
target
develop
antivir
direct
influenza
viru
protein
inhibit
process
cellular
premrna
bind
subunit
cleavag
polyadenyl
specif
factor
bind
site
also
requir
effici
viru
replic
fragment
term
span
second
third
zincfing
domain
found
specif
bind
bind
site
inhibit
influenzaaviru
replic
inhibit
process
cellular
premrna
might
indic
site
could
possibl
target
lowmolecularmass
inhibitor
hiv
replic
drugcombin
regimen
use
treatment
mycobacterium
tuberculosi
hiv
infect
achiev
greater
benefit
compound
given
individu
reduc
likelihood
drugresist
develop
might
allow
individu
drug
dose
lower
therebi
diminish
advers
effect
therapi
prophylaxi
influenzaviru
infect
combin
pegyl
interferon
ribavirin
could
complement
amantadin
rimantadin
tripledrug
combin
shown
efficaci
treatment
chronic
hcv
infect
influenza
tripledrug
regimen
might
theoret
expect
yield
benefici
outcom
three
drug
individu
activ
influenzaviru
replic
vitro
act
differ
mechan
impli
combin
might
achiev
addit
even
synergist
action
reduc
risk
emerg
drugresist
viru
variant
earli
hayden
et
al
point
addit
synergist
action
rimantadin
ribavirin
similarli
combin
pegyl
interferon
neuraminidas
inhibitor
zanamivir
oseltamivir
peramivir
could
also
consid
might
combin
ribavirin
viramidin
neuraminidas
inhibitor
combin
adamantan
amin
es
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
also
receiv
attent
vitro
rimantadin
found
act
synergist
zanamivir
oseltamivir
peramivir
reduc
extracellular
yield
influenza
viru
vivo
oseltamivir
mg
kg
per
day
amantadin
mg
kg
per
day
provid
similar
protect
influenza
associ
death
risk
mice
combin
provid
increment
protect
lethal
compar
compound
given
singleag
chemotherapi
control
studi
human
comparison
rimantadin
alon
versu
rimantadin
plu
inhal
zanamivir
hospit
adult
patient
seriou
influenza
although
preliminari
studi
point
higher
clinic
benefit
combin
zanamivir
rimantadin
sever
drug
avail
could
use
either
alon
combin
treatment
prophylaxi
therapi
pandem
influenzaviru
infect
whether
avian
human
includ
adamantan
amin
e
deriv
amantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
ribavirin
interferon
meantim
attempt
intensifi
design
develop
new
antivir
whether
base
known
molecular
target
neuraminidas
viral
uncoat
process
asyet
rel
unexplor
target
viral
rna
polymeras
latter
could
principl
target
nucleosid
nonnucleosid
inhibitor
type
approach
proven
success
case
hiv
revers
transcriptas
hcv
rna
polymeras
